FDA Sentinel Initiative Debate: How Specific Should Safety Info Be?
This article was originally published in The Gray Sheet
Executive Summary
Recent comments submitted to FDA betray stakeholder tensions surrounding what information should be made accessible, and to whom, as part of a planned medical products safety surveillance program
You may also be interested in...
FDA Sentinel Initiative Needs Safeguards To Protect Industry And Patients
A greatly expanded drug and device surveillance program could do more harm than good without proper safeguards in place, according to participants at a Dec. 16 FDA-sponsored workshop
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.